World Psoriasis Day 2025 is a time to highlight both awareness and innovation in managing this chronic, immune-mediated skin ...

In March 2025, SFA Therapeutics announced that two head-to-head preclinical studies of its oral psoriasis therapy candidate, ...

Patients with psoriasis face higher risk for several different types of cancer, according to the results of an international ...

U.S. Food and Drug Administration (FDA) has approved expanded indications for YUFLYMA® (adalimumab-aaty) and its unbranded version, to include the treatment of hidradenitis suppurativa (HS) in ...

Upadacitinib and secukinumab for PsA offers comparable improvements in skin and joint symptoms, but adalimumab offers superior pain relief.

Topicals are often the first-line treatment for psoriasis, but as the condition progresses, you may need to consider systemic treatments to manage your symptoms. Here’s what to know about your options ...

A slightly more premium option, and one that includes the same colloidal oatmeal as the Aveeno cream above, Dr Armstrong ...

Treatment with guselkumab led to improvements in disease activity over 1 year among patients with PsA and showed a high retention rate.

Codex Labs, a Silicon Valley skintech company, has launched KĀNGFÙ Cooling Recovery Gel, a game-changing skin-recovery product designed to restore and soothe skin damaged by UV radiation, phototherapy ...

The recent FDA approval of topical JAK inhibitors for children 2 years or older marks a significant advancement in pediatric ...

Jenifer Soung, MD, fo Southern California Dermatology, discussed how glucagon-like peptide-1 receptor agonists aid in treating patients with psoriatic disease. Captions are auto-generated.